ClearTrial announced the launch of ClearTrial 4.2, a release that introduces the ClearTrial Web Services API (Application Programming Interface). The ClearTrial Web Services API streamlines the integration of ClearTrial with any system that can utilize a Web Service.
"Our customers increasingly rely on ClearTrial software as a unifying platform and system of record for the planning, forecasting, and tracking of clinical projects, which requires the seamless flow of information between many other systems," noted Andrew Grygiel, Vice President of Marketing and Product Management for ClearTrial. "The new Web Services APIaims to makes the integration and interoperability of ClearTrial with their existing systems even faster and easier than before."
As one example, the ClearTrial Web Services API can be used to automate the flow of data between ClearTrial software and a resource management system such as Planisware or Primavera. This allows the resource management system, in assigning named resources to projects, to utilize the ClearTrial activity-based resource demand forecast.
ClearTrial 4.2 also delivers several features that provide flexibility and configurability in study planning, forecasting, outsourcing, and tracking. In addition, the new release offers expanded clinical intelligence and refined cost drivers.
The major new features of ClearTrial 4.2 include:
Meetings Manager – ClearTrial Meetings Manager provides a single interface to efficiently manage and track all required meetings through the life of a study. Users can create both recurring and one-off meetings of various types; choose the meeting attendees for each meeting and enter specific meeting details such as meeting attendance method and preparation time; track and override pass-through costs associated with meetings; and automatically generate new reports of meeting-related assumptions, labor fees and pass-through costs.
EDC Maturity Model – ClearTrial software has been enhanced to more accurately calculate Electronic Data Capture (EDC) labor fees and pass-through costs by leveraging a configurable EDC Maturity Model. This enhancement is based on industry research into the differing stages of EDC deployment in the industry, ranging from limited deployment and experience with EDC, to complete enterprise deployment of EDC.
Reporting Regions – ClearTrial 4.2 further advances the configurability of the software to reflect business processes by enabling the creation of user-defined regions for reporting purposes. An organization can map countries to reporting regions and use this grouping to roll-up labor fees and costs in financial reports such as the Monthly Budget.
Expanded industry intelligence – ClearTrial 4.2 has been enhanced to support 47 new indications across several therapeutic areas. ClearTrial now supports more than 200 therapeutic indications, with algorithms derived from a careful analysis of the cost and time drivers that affect each study task specifically for that indication.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.